Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales

Launched by HYWEL DDA HEALTH BOARD · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how certain chemicals in the blood and bacteria in the gut may be linked to eye damage in people with diabetes, specifically focusing on conditions called diabetic retinopathy and diabetic macular edema. The researchers aim to understand these connections in order to find ways to prevent vision loss in individuals with diabetes. To do this, they will recruit participants aged 18 to 80 who have been diagnosed with type 2 diabetes. They will need to provide blood and urine samples, and researchers will also review their medical records and eye scans to assess the severity of any eye damage.

If you decide to participate, you will help scientists gather important data that could lead to better treatments for diabetic eye disease. It’s important to note that individuals who have received specific eye treatments in the past, have certain infectious diseases, or are outside the age range of 18 to 80 cannot be included in this study. Your involvement could contribute to future advances in care for people with diabetes, potentially preserving their vision.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of type 2 diabetes mellitus
• • Male or female aged 18 - 80 inclusive
• Exclusion Criteria:
• • Participant unable or unwilling to consent to inclusion in the study
• • Prior treatment with intravitreal therapies for DMO
• • Potential participant with a known infective disease that may put the study team at risk (eg. TB, HIV, hepatitis)
• • Age 17 yo or less or 81 yo or older
• • Known underlying genetic condition affecting lipid metabolism